CY1114165T1 - Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης - Google Patents

Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης

Info

Publication number
CY1114165T1
CY1114165T1 CY20131100633T CY131100633T CY1114165T1 CY 1114165 T1 CY1114165 T1 CY 1114165T1 CY 20131100633 T CY20131100633 T CY 20131100633T CY 131100633 T CY131100633 T CY 131100633T CY 1114165 T1 CY1114165 T1 CY 1114165T1
Authority
CY
Cyprus
Prior art keywords
disorder
hydrate
eating
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CY20131100633T
Other languages
English (en)
Inventor
Kosuke Kanuma
Naoki Miyakoshi
Madoka Kawamura
Tsuyoshi Shibata
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114165(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of CY1114165T1 publication Critical patent/CY1114165T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Για την παροχή μιας νέας ένωσης, ενός φαρμακευτικώς αποδεκτού άλατος ή ενός ένυδρου άλατος αυτής χρήσιμης για την πρόληψη ή θεραπεία κατάθλιψης, αγχωδών διαταραχών (όπως γενικευμένη αγχώδης διαταραχή, διαταραχή μετατραυματικού στρες, διαταραχή πανικού, ψυχαναγκαστική-καταναγκαστική διαταραχή ή κοινωνική αγχώδης διαταραχή), διαταραχής ελλειμματικής προσοχής, μανίας, μανιοκαταθλιπτικής νόσου, σχιζοφρένειας, διαταραχών της διάθεσης, στρες, διαταραχών του ύπνου, κρίσεων, εξασθένησης της μνήμης, γνωστικής εξασθένησης, άνοιας, αμνησίας, παραληρήματος, παχυσαρκίας, διαταραχής στην πρόσληψη τροφής, διαταραχής της όρεξης, υπερφαγίας, βουλιμίας, φοβίας στο φαγητό, διαβήτη, καρδιαγγειακών νόσων, υπέρτασης, δυσλιπιδαιμίας, εμφράγματος του μυοκαρδίου, κινητικής διαταραχής (όπως νόσος του Πάρκινσον, επιληψία, σπασμός ή τρόμος), φαρμακευτικής κατάχρησης, εθισμού σε ουσίες ή σεξουαλικής δυσλειτουργίας, με βάση μια ανταγωνιστική του υποδοχέα ορμόνης συγκέντρωσης μελανίνης (ΜCH) δράση. ΛΥΣΗ Μια ένωση, ένα φαρμακευτικώς αποδεκτό άλας ή ένα ένυδρο άλας αυτής που παριστάνεται με τον τύπο (I).
CY20131100633T 2008-10-02 2013-07-25 Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης CY1114165T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008257072 2008-10-02
EP09817928.6A EP2344471B1 (en) 2008-10-02 2009-09-30 7-piperidinoalkyl-3,4-dihydroquinolone derivative

Publications (1)

Publication Number Publication Date
CY1114165T1 true CY1114165T1 (el) 2016-08-31

Family

ID=42073652

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100633T CY1114165T1 (el) 2008-10-02 2013-07-25 Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης

Country Status (29)

Country Link
US (1) US8461182B2 (el)
EP (1) EP2344471B1 (el)
JP (1) JP5541279B2 (el)
KR (1) KR20110067026A (el)
CN (1) CN102239159B (el)
AR (1) AR073727A1 (el)
AU (1) AU2009300607C1 (el)
BR (1) BRPI0925343A2 (el)
CA (1) CA2739513A1 (el)
CL (1) CL2011000734A1 (el)
CO (1) CO6321164A2 (el)
CY (1) CY1114165T1 (el)
DK (1) DK2344471T3 (el)
ES (1) ES2424393T3 (el)
HK (1) HK1159622A1 (el)
HR (1) HRP20130728T1 (el)
IL (1) IL212070A (el)
MX (1) MX2011003500A (el)
MY (1) MY154337A (el)
NZ (1) NZ592008A (el)
PE (1) PE20110410A1 (el)
PL (1) PL2344471T3 (el)
PT (1) PT2344471E (el)
RS (1) RS52964B (el)
RU (1) RU2498981C2 (el)
SI (1) SI2344471T1 (el)
UA (1) UA105187C2 (el)
WO (1) WO2010038901A1 (el)
ZA (1) ZA201102315B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011219467A (ja) * 2010-03-26 2011-11-04 Taisho Pharmaceutical Co Ltd ７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
AU2013259624B2 (en) 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
WO2013169704A2 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CN105228604A (zh) * 2013-03-12 2016-01-06 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3256450B1 (en) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3307738B1 (en) 2015-06-11 2022-04-20 The Regents of the University of Michigan Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
CA3002850A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282222B6 (sk) * 1995-09-15 2001-12-03 Sanofi-Synthelabo Deriváty 2(1h)-chinolónu, spôsob ich prípravy a ich použitie ako liečiv
KR20040058191A (ko) * 2001-10-01 2004-07-03 다이쇼 세이야꾸 가부시끼가이샤 Ｍｃｈ 수용체 안타고니스트
CN1585751A (zh) * 2001-10-25 2005-02-23 武田药品工业株式会社 喹啉化合物
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
EP1611109A4 (en) * 2003-03-31 2009-06-24 Taisho Pharmaceutical Co Ltd NOVEL QUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USE
US20050209274A1 (en) * 2004-02-26 2005-09-22 Lynch John K Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US20090036448A1 (en) * 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
US20080090863A1 (en) * 2004-09-30 2008-04-17 Taisho Pharmaceutical Co., Ltd. Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
JPWO2008044632A1 (ja) * 2006-10-06 2010-02-12 大正製薬株式会社 １−ナフチルアルキルピペリジン誘導体

Also Published As

Publication number Publication date
CL2011000734A1 (es) 2011-09-23
MX2011003500A (es) 2011-05-02
CN102239159B (zh) 2014-06-25
DK2344471T3 (da) 2013-10-07
CN102239159A (zh) 2011-11-09
HRP20130728T1 (en) 2013-10-11
EP2344471B1 (en) 2013-07-24
ZA201102315B (en) 2012-06-27
IL212070A (en) 2014-07-31
AU2009300607B2 (en) 2014-02-27
ES2424393T3 (es) 2013-10-01
EP2344471A1 (en) 2011-07-20
AU2009300607A1 (en) 2010-04-08
KR20110067026A (ko) 2011-06-20
AU2009300607C1 (en) 2014-08-07
CA2739513A1 (en) 2010-04-08
EP2344471A4 (en) 2012-05-30
PT2344471E (pt) 2013-08-01
JP2012504549A (ja) 2012-02-23
BRPI0925343A2 (pt) 2015-07-28
SI2344471T1 (sl) 2013-11-29
AR073727A1 (es) 2010-11-24
RU2498981C2 (ru) 2013-11-20
JP5541279B2 (ja) 2014-07-09
HK1159622A1 (en) 2012-08-03
UA105187C2 (uk) 2014-04-25
PE20110410A1 (es) 2011-07-02
MY154337A (en) 2015-05-29
WO2010038901A1 (en) 2010-04-08
RU2011117161A (ru) 2012-11-10
IL212070A0 (en) 2011-06-30
PL2344471T3 (pl) 2013-12-31
NZ592008A (en) 2011-12-22
RS52964B (en) 2014-02-28
US8461182B2 (en) 2013-06-11
CO6321164A2 (es) 2011-09-20
US20110178304A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
CY1114165T1 (el) Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης
BRPI0408910A (pt) composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica
WO2005095357A3 (en) Pyrimidine derivatives and methods of treatment related to the use thereof
EA201070903A1 (ru) Замещенные спироциклические производные пиперидина как лиганды гистамин-3(h) рецептора
TW200626152A (en) Pyridine derivatives and pharmaceutical compositions and uses thereof
JP2009536161A5 (el)
ATE448230T1 (de) Für die behandlung von obesitas geeignete tricyclische amidderivate
BRPI0519597A2 (pt) derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
ATE539063T1 (de) Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen
NO20075086L (no) Behandling av Parkinsons sykdom, obstruktiv sovn apne, demens med Lewy legemer, vaskulaer demens med ikke-imidazol alkylamin histamin H3-reseptor ligander
DE602006008323D1 (de) 6-substituierte- 2,3,4,5-tetrahydro-1h-benzoädüazepine als 5-ht2c-rezeptoragonisten
CL2013003485A1 (es) Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes.
DE602008003221D1 (de) Prolinamidderivate als nk3-antagonisten
EA200970596A1 (ru) Соединения с сочетанием антагонистической активности в отношении каннабиноидных рецепторов сви ингибирующей активности в отношении ацетилхолинэстеразы
BR112012003916A2 (pt) derivados de pirrolidinas como antagonistas de receptores nk3
CR10036A (es) Procedimientos para la preparación de derivados de ciclopropilamida
EA201001799A1 (ru) Новые способы получения пиперазинильных и диазепанильных производных бензамида
ATE323094T1 (de) Antidepressiv wirkende cycloalkylaminderivate von mit heterocyclen kondensierten benzodioxanen
ATE472538T1 (de) 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden
DE602006003225D1 (de) Chlorsubstituierte guanidine
FR2873371B1 (fr) Nouvelle methode de synthese de 2,5 dioxane 1,4 diones
EA015500B9 (ru) Новые антагонисты мсн рецепторов